Clinical Trial of ARQ 761 in Advanced Solid Tumors

NCT01502800 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

91

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: ARQ 761
DRUG: ARQ 761 Weekly Administration
DRUG: Bi-Weekly Administration of ARQ 761
DRUG: Two Consecutive Weeks Administration of ARQ 761 with one week of rest

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]